Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer.
Gomez S, Cox OL, Walker RR 3rd, Rentia U, Hadley M, Arthofer E, Diab N, Grundy EE, Kanholm T, McDonald JI, Kobyra J, Palmer E, Noonepalle S, Villagra A, Leitenberg D, Bollard CM, Saunthararajah Y, Chiappinelli KB. Gomez S, et al. Among authors: saunthararajah y. J Immunother Cancer. 2022 Nov;10(11):e004974. doi: 10.1136/jitc-2022-004974. J Immunother Cancer. 2022. PMID: 36343976 Free PMC article.
Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies.
Woost PG, William BM, Cooper BW, Ueda Oshima M, Otegbeye F, De Lima MJ, Wald D, Mahfouz RZ, Saunthararajah Y, Stefan T, Jacobberger JW. Woost PG, et al. Among authors: saunthararajah y. Cytometry B Clin Cytom. 2024 Jan;106(1):11-24. doi: 10.1002/cyto.b.22158. Epub 2024 Feb 12. Cytometry B Clin Cytom. 2024. PMID: 38345160
Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy.
Biswas S, Kang K, Ng KP, Radivoyevitch T, Schalper K, Zhang H, Lindner DJ, Thomas A, MacPherson D, Gastman B, Schrump DS, Wong KK, Velcheti V, Saunthararajah Y. Biswas S, et al. Among authors: saunthararajah y. Cell Rep. 2023 Aug 29;42(8):113016. doi: 10.1016/j.celrep.2023.113016. Epub 2023 Aug 18. Cell Rep. 2023. PMID: 37597186 Free PMC article.
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.
Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica RA, Kornblum N, Shah N, Levitz D, Rockwell B, Shapiro LC, Gupta R, Pradhan K, Xue X, Munoz A, Dhawan A, Fehn K, Comas M, Verceles JA, Jonas BA, Kambhampati S, Shi Y, Braunschweig I, Cooper DL, Konopleva M, Feldman EJ, Verma A. Goldfinger M, et al. Among authors: saunthararajah y. Blood. 2024 Nov 28;144(22):2360-2363. doi: 10.1182/blood.2024025834. Blood. 2024. PMID: 39316768 Free article.
A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.
Levitz D, Saunthararajah Y, Fedorov K, Shapiro LC, Mantzaris I, Shastri A, Kornblum N, Sica RA, Shah N, Konopleva M, Gritsman K, Braunschweig I, Cooper DL, Pradhan K, Verma A, Feldman EJ, Goldfinger M. Levitz D, et al. Among authors: saunthararajah y. Clin Cancer Res. 2023 Aug 1;29(15):2774-2780. doi: 10.1158/1078-0432.CCR-23-0842. Clin Cancer Res. 2023. PMID: 37341641
163 results